Bologna

• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patien … Ended
  2024-517322-26-00 1 2025-06-06 EGFR-Mutant Non-Small Cell Lung Cancer
• Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP Ended
  2024-515386-34-00 4 2025-05-29 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP Ended
  2024-518364-12-00 4 2025-05-09 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic … Ended
  2023-507771-22-01 5 2025-04-03 Primary Biliary Cholangitis (PBC)
• A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 Ended
  2024-515452-20-00 4 2025-04-01 Narcolepsy Type 2
• A study to evaluate safety and efficacy of Empasiprubart in adults with Dermatomyositis Ended
  2023-508337-14-00 4 2025-03-18 Myositis, Dermatomyositis
• Phase 1/2 Study of Cobolimab plus Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors Ended
  2024-511350-41-00 9 2025-03-13 Relapsed/Refractory Tumors
• A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 Ended
  2024-511112-24-00 4 2025-01-17 Narcolepsy Type 1
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-024) Ended
  2024-512278-92-00 4 2024-12-09 Pulmonary Arterial Hypertension (PAH)
• A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1) Ended
  2024-514559-13-00 10 2024-11-26 Focal Epilepsy
• A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended
  2023-510341-19-00 5 2024-11-14 acne vulgaris
• Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN … Ended
  2023-508812-45-00 10 2024-11-11 Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
• Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat … Ended
  2023-508474-29-00 4 2024-10-30 Dermatitis, Atopic
• A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended
  2024-511998-30-00 5 2024-10-18 Narcolepsy with Cataplexy (Narcolepsy Type 1)
• A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers. Ended
  2023-506997-11-00 1 2024-10-09 CD123-Positive Hematological Malignancies: Module 1 focuses on R/R Acu
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe … Ended
  2024-511225-64-00 4 2024-09-18 Alopecia areata
• A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended
  2023-508465-32-00 5 2024-09-03 Narcolepsy with Cataplexy (Narcolepsy Type 1)
• A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni … Ended
  2023-505755-40-00 4 2024-08-16 Chronic kidney disease
• Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended
  2023-508679-34-00 4 2024-07-30 Ulcerative Colitis
• A trial to learn how well balcinrenone in combination with dapagliflozin works and how safe it is compared to dapagliflozin alone in adults … Ended
  2023-509709-63-00 4 2024-07-30 Chronic Kidney Disease and Albuminuria
• A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplas … Ended
  2023-509947-29-00 4 2024-07-18 Anemia in patients with very low, low or intermediate risk myelodyspla
• A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment … Ended
  2023-509738-20-00 6 2024-07-11 Plaque Psoriasis
• Phase 2b study to investigate the safety and efficacy of TIN816 in SA-AKI Ended
  2023-505903-22-00 4 2024-07-02 Sepsis associated acute kidney injury
• Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar ) Ended
  2023-506229-12-00 4 2024-06-26 Osteosarcoma in Children

Showing 697–720 of 875 trials